Share

In This Article

  1. What These Peptides Actually Are
  2. What The Human Research Shows
  3. Who Uses It And Why
  4. Dosing - What Clinics Typically Use
  5. Side Effects To Know About
  6. The Honest Bottom Line

What These Peptides Actually Are

To understand this combination, you need to understand how your body naturally produces growth hormone. It's a two-signal system:

CJC-1295 mimics Signal 1. Ipamorelin mimics Signal 2. Together, they hit both switches at the same time.

CJC-1295

CJC-1295 is a modified version of GHRH (growth hormone releasing hormone). The natural version of GHRH is broken down by your body in minutes. CJC-1295 has been modified to last much longer - it binds to albumin in your blood (the DAC version) or has a modified amino acid sequence (modified GRF 1-29, often called "CJC-1295 without DAC"). This means instead of a brief spike in GH, you get a sustained elevation that lasts hours to days.

Ipamorelin

Ipamorelin is a synthetic version of ghrelin - but a very selective one. This is its key advantage. Natural ghrelin increases growth hormone, but it also increases cortisol (stress hormone) and prolactin. Ipamorelin triggers GH release without touching cortisol or prolactin. This selectivity is what makes it stand out from older secretagogues like GHRP-6 or GHRP-2, which had more side effects because they hit multiple hormone pathways.

Moderate - Human Pharmacokinetic Data

What The Combination Does

What The Human Research Shows

The CJC-1295 Trial (2006)

A clinical study in healthy adults aged 21-61 showed that subcutaneous CJC-1295 produced sustained, dose-dependent increases in both GH and IGF-1. At doses of 30 and 60 mcg/kg, it was well tolerated. IGF-1 levels increased by 36-69% and remained elevated for up to 28 days after a single injection. This was a proper pharmacokinetic study - measuring what the drug does in the body - and the results were clear.

What We Don't Have

Here's the gap: there are no published, peer-reviewed clinical trials demonstrating that this combination actually delivers the outcomes people use it for - better body composition, improved recovery, anti-ageing effects. The pharmacokinetic data is solid (it raises GH and IGF-1). The outcome data (does that translate to meaningful clinical benefits in healthy adults?) doesn't exist in proper trials.

We know GH and IGF-1 are involved in muscle repair, fat metabolism, bone density, skin quality, and sleep architecture. We know these peptides reliably raise those hormones. What's missing is the controlled evidence connecting those elevated levels to real-world results in healthy people using these specific compounds.

Who Uses It And Why

Dosing - What Clinics Typically Use

Side Effects To Know About

The Honest Bottom Line

CJC-1295 and ipamorelin reliably raise growth hormone and IGF-1 levels - the pharmacokinetic evidence is clear. What's missing is the controlled clinical evidence that this translates into the specific outcomes people are paying for (better body composition, anti-ageing, recovery). The biological rationale is sound, the mechanism is well-understood, and the safety profile appears favourable compared to synthetic GH. But "should raise GH safely" and "proven to deliver results" are different claims. Know which one you're acting on.

For the full peptide landscape, read the Complete Peptide Guide.

This article is for educational purposes only. It is not medical advice. Peptides discussed here may not be approved for human use in your country. Always consult a qualified medical professional before making any health decisions.